Escalating efforts to contain China’s first Delta variant outbreak will hurt some sectors of the economy. But if they are as successful as they have been in the past, the overall damage will be fleeting and small. Meanwhile, a rise in infections classed as critical in China over recent days raises questions over whether China’s vaccines are as effective at reducing severity of infection from the Delta variant as several studies have shown they are against the regular variety. That matters beyond China’s borders: the government this week said that China is now exporting 200bn vaccine doses per month and that this pace will increase over the rest of the year.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services